Amgen’s Otezla shows promise in psoriatic arthritis
The inflammatory form of arthritis is estimated to affect nearly 38 million people worldwide
Read Moreby Jen Brogan | May 31, 2023 | News | 0
The inflammatory form of arthritis is estimated to affect nearly 38 million people worldwide
Read Moreby John Pinching | Jul 6, 2022 | News | 0
Clinical trial evidence suggests that Tremfya is effective when compared with a placebo
Read Moreby Lucy Parsons | May 28, 2021 | News | 0
Tremfya has already been recommended for NHS use to treat eligible patient with moderate-to-severe plaque psoriasis
Read Moreby Lucy Parsons | Mar 2, 2021 | News | 0
Label update includes data for axial manifestations of psoriatic arthritis
Read Moreby Lucy Parsons | Jan 26, 2021 | News | 0
Oral JAK inhibitor approved for psoriatic arthritis and ankylosing spondylitis
Read Moreby Lucy Parsons | Jan 7, 2021 | News | 0
KEEPsAKE-1 and KEEPsAKE-2 studies demonstrated significant improvements in Skyrizi-treated patients
Read Moreby Selina McKee | Nov 26, 2020 | News | 0
Tremfya is a first-in-class treatment for the disease, shown to improve disease measures and quality of life
Read Moreby Lucy Parsons | Nov 5, 2020 | News | 0
Synovitis (joint lining inflammation) can lead to joint damage in psoriatic arthritis patients
Read Moreby Selina McKee | Jun 2, 2020 | News | 0
Rinvoq is a selective and reversible JAK inhibitor being studied in several immune-mediated inflammatory diseases
Read Moreby Anna Smith | May 2, 2019 | News | 0
The new educational campaign is called ‘Six Domains: One Disease‘.
Read Moreby Selina McKee | Oct 9, 2018 | News | 0
The Scottish Medicines Consortium has endorsed NHS funding for four therapies, offering new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis.
Read Moreby Selina McKee | Sep 20, 2018 | News | 0
The European Commission has approved Mylan and Fujifilm Kyowa Kirin Biologics’ Humira biosimiar Hulio.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
